- Skin cancers grow like icebergs — microscopic cancer cells extend beyond the visible border in unpredictable patterns — this subclinical extension is why surgeons must remove a margin of normal-appearing skin around every skin cancer
- For BCC: a 4 mm margin clears more than 95% of well-defined tumors under 2 cm — aggressive subtypes and recurrent tumors require wider margins or Mohs surgery
- For SCC: standard-risk tumors need 4 mm margins, but high-risk SCC requires at least 6 mm or Mohs — perineural invasion, deep invasion, and poor differentiation all elevate risk
- For melanoma: margins range from 0.5 cm (in situ) to 2 cm (thick tumors) — six landmark randomized trials established the guidelines surgeons follow today
- Mohs surgery examines 100% of the surgical margin versus roughly 1% with standard pathology — this is the fundamental reason Mohs achieves the highest cure rates
- The only randomized trial comparing Mohs to standard excision found a 3-fold difference at 10 years — 4.4% recurrence with Mohs versus 12.2% with standard excision for primary facial BCC
- A 2024 meta-analysis of 17 studies confirmed Mohs cuts recurrence risk by half — relative risk 0.48 across both BCC and SCC
Evidence Snapshot
- BCC margins: A 4 mm margin clears more than 95% of well-demarcated tumors under 2 cm; aggressive or recurrent tumors require Mohs (Wolf & Zitelli, 1987; Quazi et al., 2020)
- SCC margins: Standard-risk SCC needs 4 mm; high-risk SCC needs at least 6 mm or Mohs. Perineural invasion changes everything — 47% recurrence with conventional treatment versus 0% with Mohs (Brodland & Zitelli, 1992; Rowe et al., 1992)
- Melanoma margins: Based on six randomized trials — 0.5–1 cm for in situ, 1 cm for thin melanoma, 1–2 cm for intermediate, 2 cm for thick melanoma (Swetter et al., 2021; Sharib et al., 2022)
- Mohs vs. excision: The only randomized trial with 10-year follow-up found 4.4% Mohs recurrence versus 12.2% standard excision for primary BCC, and 3.9% versus 13.5% for recurrent BCC (van Loo et al., 2014)
- Evidence base: This article cites 23 PubMed-indexed studies including landmark margin analyses, randomized trials, systematic reviews, a 2024 meta-analysis, and current AAD, NCCN, and European clinical guidelines
Why does my surgeon need to take more skin than just the visible cancer?
Skin cancers grow like icebergs — what you see on the surface is only part of the tumor. Microscopic cancer cells extend beyond the visible border in unpredictable patterns, which is why surgeons must remove a margin of normal-appearing skin around every skin cancer to ensure complete removal.
This is the single most common question patients ask after hearing their treatment plan. You looked at a spot that seemed small — maybe the size of a pencil eraser — and now your surgeon is talking about removing an area several times larger. It feels excessive. It is not.
The reason is biology. Skin cancers do not grow in neat, well-defined circles. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) send microscopic projections outward from the visible tumor — tendrils of cancer cells that are invisible to the naked eye. If a surgeon removes only what they can see, they leave cancer behind. The tumor recurs. The patient needs another surgery, often a larger one, in the same location.
This concept — subclinical extension — is why every skin cancer surgery involves removing a margin of clinically normal tissue surrounding the visible tumor. The width of that margin is not arbitrary. It is determined by decades of research examining how far different types of skin cancer extend beyond their visible borders.
Think of it like pulling a weed: if you cut the dandelion at the surface, it looks gone — but the roots are still underneath, and the weed grows back. A surgeon who removes only the visible cancer is cutting the weed at the surface. Removing a margin means pulling the roots too.
What margin width is recommended for basal cell carcinoma?
The foundational study on BCC margins was published by Wolf and Zitelli in 1987. They examined 117 previously untreated, well-demarcated basal cell carcinomas using Mohs micrographic surgery to map the true extent of each tumor. Their finding was clear: a minimum margin of 4 mm was necessary to completely eradicate the tumor in more than 95% of cases for tumors smaller than 2 cm (Wolf & Zitelli, 1987).
This study is nearly four decades old and remains the standard reference because its methodology was rigorous — it used Mohs surgery to verify exactly where each tumor ended, giving a precise measurement of subclinical extension rather than an estimate.
A 2020 systematic review of 15 studies encompassing 3,843 lesions by Quazi and colleagues confirmed these findings and added nuance: low-risk, well-demarcated BCC under 2 cm may be adequately treated with 3 mm margins, while high-risk or larger BCC requires 4–6 mm margins, and recurrent, morpheaform, or poorly defined BCC should be treated with Mohs micrographic surgery (Quazi et al., 2020).
Cerci and colleagues published a large single-institution analysis of 1,131 BCCs treated with Mohs surgery in 2020 and found that larger surgical defects — indicating greater subclinical extension — correlated strongly with aggressive histologic subtypes, recurrent tumors, and tumors on the nose (Cerci et al., 2020). This confirmed what the earlier studies predicted: the tumors that extend farthest beyond their visible borders are precisely the ones most likely to recur if treated with fixed-margin excision.
Why 4 mm and not 2 mm or 10 mm?
The margin is a balance between two competing goals. Remove too little and you leave cancer behind. Remove too much and you create an unnecessarily large wound — which means a bigger scar, more tissue loss, and potentially more complex reconstruction, especially on the face.
The Wolf and Zitelli data showed that at 2 mm margins, only about 75% of BCCs were completely cleared. At 3 mm, approximately 85%. The jump to 4 mm reached over 95%. Beyond 4 mm, the incremental benefit dropped off — you were removing more tissue for diminishing returns in most low-risk tumors. Ünverdi and colleagues revisited this question in 2020 and confirmed that 3 mm margins can be adequate for small, well-defined BCCs, but emphasized that this only holds when the tumor is truly low-risk (Ünverdi et al., 2020).
BCC margin recommendations by risk level
| BCC Risk Level | Recommended Margin | Clearance Rate | When Mohs Is Preferred |
|---|---|---|---|
| Low-risk, well-defined, under 2 cm | 3–4 mm | Over 95% at 4 mm | Cosmetically sensitive areas (nose, eyelids, ears, lips) |
| High-risk (over 2 cm, aggressive subtype, poorly defined) | 4–6 mm | Variable by subtype | Yes — aggressive subtypes have unpredictable extension |
| Recurrent (previously treated) | Not reliable with standard excision | Recurrence 12.2% with excision vs. 4.4% with Mohs at 10 years | Strongly recommended |
| Morpheaform or infiltrative | Standard margins often inadequate | Poor with fixed margins | Strongly recommended — these subtypes show extensive subclinical spread |
Sources: Wolf & Zitelli, 1987; Quazi et al., 2020; van Loo et al., 2014
The morpheaform (or sclerosing) subtype of BCC is the most difficult to treat with standard excision because it grows in thin, finger-like projections that extend far beyond the visible border. Studies have shown subclinical extension of 7 mm or more in these tumors — well beyond even a 4 mm margin. This is why guidelines recommend Mohs surgery for every morpheaform BCC, regardless of size or location.
What about squamous cell carcinoma — does it need wider margins?
Squamous cell carcinoma is a different animal from BCC. While BCC almost never metastasizes, SCC carries meaningful risks of both local recurrence and distant spread — particularly when high-risk features are present. This makes margin selection for SCC even more consequential.
The landmark study is Brodland and Zitelli's 1992 prospective analysis, which used Mohs micrographic surgery to map subclinical extension in primary cutaneous SCC. Their findings established two clear tiers: standard-risk SCC required 4 mm margins for adequate clearance, while high-risk SCC — defined as tumors 2 cm or larger, histologic grade 2 or higher, invasion into subcutaneous tissue, or location in high-risk anatomic sites — required at least 6 mm margins (Brodland & Zitelli, 1992).
The 2018 AAD guidelines for SCC management reinforced these findings and further codified risk stratification as the standard approach — not one-size-fits-all margin widths, but margins tailored to tumor-specific risk factors (Kim et al., 2018b). The 2023 European consensus guidelines from Stratigos and colleagues adopted a similar risk-adapted framework, recommending at least 6 mm clinical margins for high-risk cSCC and Mohs surgery when tissue conservation is critical (Stratigos et al., 2023).
SCC risk factors that demand wider margins or Mohs
Rowe, Carroll, and Day published a comprehensive prognostic analysis identifying key variables correlated with higher recurrence and metastasis in SCC (Rowe et al., 1992):
- Tumor size over 2 cm — recurrence rates roughly double
- Depth of invasion beyond subcutaneous fat — dramatically higher metastasis risk
- Poor histologic differentiation — conventional treatment recurrence rates increase substantially
- Perineural invasion — Mohs achieved 0% recurrence versus 47% with conventional treatment in this high-risk subset
- Location — ear, lip, and temple carry higher risk
- Recurrent tumors — previously treated SCC that returns
- Immunosuppression — transplant recipients have dramatically elevated SCC risk and more aggressive tumor biology
Zakhem and colleagues published a 2023 analysis in JAMA Dermatology examining risk factors for poor outcomes in primary cSCC and confirmed that tumor thickness, poor differentiation, and perineural invasion remained the strongest independent predictors of recurrence and metastasis (Zakhem et al., 2023).
The perineural invasion finding is particularly striking: conventional treatment resulted in 47% recurrence, while Mohs surgery achieved 0% recurrence in the same high-risk subset. For any SCC showing perineural involvement, the margin control offered by 100% histologic examination is not optional — it is the standard of care.
What are the recommended margins for melanoma?
Melanoma margins follow a different logic than BCC or SCC. Because melanoma carries a significant risk of metastasis, the primary concern is not just local recurrence but also whether wider excision improves survival. Six landmark randomized controlled trials — conducted over four decades — established the margin guidelines that surgeons follow worldwide today (Sharib et al., 2022).
Current NCCN margin recommendations for melanoma
| Melanoma Stage | Breslow Thickness | Recommended Margin | Evidence Base |
|---|---|---|---|
| In situ (confined to epidermis) | N/A | 0.5–1.0 cm | Clinical consensus; Mohs with immunostaining increasingly used |
| Thin melanoma | Up to 1.0 mm | 1.0 cm | Randomized trial data |
| Intermediate melanoma | 1.01–2.0 mm | 1–2 cm | Randomized trial data |
| Thick melanoma | Over 2.0 mm | 2.0 cm | Randomized trial data |
Source: Swetter et al., 2021 (NCCN Guidelines v2.2021)
The key finding across all six trials is that wider margins do not improve survival for any stage of melanoma. The surgical margin affects local recurrence rates but not distant metastasis or overall survival. This is why margins were progressively narrowed from 5 cm (the historical standard) to the current recommendations — surgeons were removing enormous amounts of tissue with no survival benefit (Sharib et al., 2022).
What about melanoma in situ?
Melanoma in situ presents a unique challenge because these tumors — particularly the lentigo maligna subtype — can have extensive subclinical extension along sun-damaged skin. Standard 0.5 cm margins may leave residual disease in a significant percentage of cases, which is why many fellowship-trained Mohs surgeons now use Mohs surgery with immunostaining (such as MART-1 or SOX10 stains) to achieve complete margin clearance while preserving tissue. The 2012 AAD/ACMS appropriate use criteria rated melanoma in situ as appropriate for Mohs in 10 of 12 scenarios evaluated — the highest appropriateness rate of any cancer type (Connolly et al., 2012).
The original recommended margin for melanoma was 5 cm — meaning surgeons removed a circle of skin 10 cm (about 4 inches) across for even a small melanoma. This was based on a single uncontrolled case series from the 1800s. Randomized trials eventually proved that margins this wide offered no survival benefit, and today's guidelines recommend margins of 1–2 cm for most melanomas — sparing patients from unnecessarily disfiguring surgery.
How does Mohs surgery change the margin equation?
Standard excision uses predetermined margins — the surgeon removes a fixed width of tissue around the visible cancer based on guidelines. The removed tissue is sent to a pathology lab, where a technician cuts a few representative slices (called "bread-loaf" sections) and examines them under a microscope. This process samples roughly 1% of the actual surgical margin — and some estimates place it as low as 0.2% (Helm et al., 2024). If cancer happens to be present in the 99% that was not examined, it goes undetected.
To put this in perspective: bread-loaf sectioning at 2 mm intervals has only a 37% chance of detecting positive margins. At 4 mm intervals — a common practice — the detection rate drops to 19%. The vast majority of the margin is simply never examined.
Mohs micrographic surgery fundamentally changes this equation. The Mohs surgeon removes a thin layer of tissue, maps its precise orientation, and processes it so that 100% of the deep and peripheral margins are examined under a microscope. If any cancer cells remain, their exact location is identified on the map, and another targeted layer is removed — only where cancer persists. This cycle repeats until the entire margin is clear.
The only randomized trial: Mohs versus standard excision
Smeets and colleagues conducted the only randomized controlled trial directly comparing Mohs surgery to standard surgical excision for facial BCC. Published in The Lancet in 2004, the initial 5-year results showed a trend favoring Mohs that did not reach statistical significance (Smeets et al., 2004).
But the 10-year follow-up, published by van Loo and colleagues in 2014, told the definitive story:
| Tumor Type | Mohs Recurrence (10 years) | Standard Excision Recurrence (10 years) |
|---|---|---|
| Primary BCC | 4.4% | 12.2% |
| Recurrent BCC | 3.9% | 13.5% |
For recurrent BCC, Mohs cut the recurrence rate by more than 70%. This is the strongest level of evidence available — a randomized trial with long-term follow-up — and it confirms what decades of observational data had suggested.
Meta-analysis confirms the advantage across 17 studies
Lacerda and colleagues published a systematic review and meta-analysis in 2024 that pooled data from 17 studies (two randomized trials and fifteen cohort studies) comparing Mohs surgery to conventional excision for both BCC and SCC. Among 3,050 tumors treated with Mohs, 82 recurred (3.1%). Among 3,453 tumors treated with conventional surgery, 209 recurred (5.3%). The combined relative risk was 0.48 (95% CI 0.36–0.63) — meaning Mohs surgery cut recurrence risk approximately in half (Lacerda et al., 2024).
The difference between Mohs and standard excision is not about surgical skill — it is about how much of the margin gets examined. Standard pathology sees roughly 1% of the margin and hopes for the best. Mohs sees 100% and knows for certain. That difference in information is what drives the difference in recurrence.
When does a skin cancer qualify for Mohs surgery?
One of the most common misunderstandings patients encounter is the idea that Mohs surgery is reserved for "serious" or "advanced" skin cancers. In reality, the decision is based on a nuanced set of criteria that weigh the tumor's characteristics against the consequences of recurrence.
In 2012, the American Academy of Dermatology, American College of Mohs Surgery, and two additional professional societies published comprehensive appropriate use criteria (AUC) for Mohs surgery. A panel of experts evaluated 270 specific clinical scenarios using the RAND/UCLA appropriateness method and found Mohs surgery appropriate in the majority of evaluated scenarios (Connolly et al., 2012):
- BCC: 53 of 69 scenarios (77%) rated appropriate for Mohs
- SCC: 102 of 143 scenarios (71%) rated appropriate for Mohs
- Melanoma in situ: 10 of 12 scenarios (83%) rated appropriate for Mohs
- Overall: 200 of 270 scenarios (74%) rated appropriate for Mohs
Murray and colleagues conducted a systematic review of all published Mohs indications literature and confirmed that location, histologic subtype, recurrent status, and patient risk factors consistently emerged as the primary drivers of appropriateness — not tumor size alone (Murray et al., 2019).
Key factors that make Mohs the preferred approach
| Factor | Why Mohs Is Indicated |
|---|---|
| Location — face, ears, nose, eyelids, lips, genitals, hands, feet | Tissue conservation matters most where every millimeter affects cosmetic or functional outcome |
| Aggressive histologic subtype — morpheaform, infiltrative, micronodular BCC; poorly differentiated SCC | These subtypes extend far beyond visible borders; fixed margins frequently miss residual cancer |
| Recurrent tumors | Scar tissue from prior treatment obscures borders; recurrence rates with re-excision are 3 times higher than with Mohs |
| Large tumors (over 2 cm) | Larger tumors have more unpredictable subclinical extension |
| Perineural invasion | Standard treatment: 47% recurrence; Mohs: 0% recurrence (Rowe et al., 1992) |
| Immunosuppressed patients | Transplant recipients have dramatically higher SCC risk and more aggressive tumor biology |
The 2018 AAD guidelines for both BCC and SCC management further reinforced this risk-stratified approach, recommending Mohs for high-risk tumors in cosmetically and functionally important areas (Kim et al., 2018a; Kim et al., 2018b).
What happens if my margins come back positive after standard excision?
If pathology shows cancer at the margin after standard excision, it means the cancer was not completely removed. This does not mean the cancer has spread — it means microscopic tumor cells were present at the edge of the tissue that was removed.
The standard approach is either a wider re-excision or Mohs surgery. Daviti and colleagues published real-world data in 2023 showing that positive margins after BCC excision do not always lead to clinical recurrence — but the uncertainty itself is the problem. Without re-treatment, there is no way to know whether residual cancer cells will regrow (Daviti et al., 2023).
For recurrent tumors — cancers that come back after previous treatment — the challenge becomes significantly harder. Scar tissue from the prior surgery distorts the tissue planes, making it difficult to distinguish between cancer and fibrosis. This is why recurrence rates with standard re-excision are substantially higher than with Mohs surgery for these cases.
If you have been told your margins are positive, do not panic — but do ask about Mohs surgery as a next step, especially if the cancer is on the face. Mohs provides definitive margin assessment that eliminates the uncertainty of repeated standard excisions.
What does this mean for my specific situation?
The right treatment depends on your specific tumor — its type, size, location, histologic features, and your personal risk factors. A fellowship-trained Mohs surgeon can evaluate all of these variables and recommend the approach that gives you the highest cure rate with the smallest scar.
If your doctor has recommended removing more tissue than you expected, or if Mohs surgery has been suggested, it is almost certainly because your tumor has features that warrant it. The evidence is clear that under-treatment of skin cancer — removing too little tissue to save a smaller scar — leads to recurrence, which ultimately means more surgery, a larger wound, and a worse cosmetic outcome than getting it right the first time.
The question to ask is not "why so much skin?" but rather "how can we be certain it is all gone?" For many skin cancers, Mohs surgery provides the most definitive answer available in medicine.
Test Your Surgical Margins Knowledge
4 game modes to test what you've learned. Pick your style.
Choose your mode
Take your time. Get detailed explanations after each question.
15-second timer. Score points for speed. Build streaks for multipliers.
Pick your category. Pick your value. How much do you know?
Progressive difficulty. 3 lifelines. How far can you go?
Frequently Asked Questions
1. How much skin will actually be removed during Mohs surgery?
Mohs surgery is designed to remove the least amount of tissue necessary for complete cancer clearance. The initial layer is typically very thin — just the visible tumor plus a 1–2 mm margin. If cancer remains at any point on the margin, another targeted layer is taken only where needed. Most tumors are cleared in one to two stages, resulting in a wound only slightly larger than the tumor itself.
2. Is a 4 mm margin always enough for BCC?
For well-demarcated, low-risk BCC under 2 cm, a 4 mm margin clears more than 95% of tumors. However, aggressive subtypes (morpheaform, infiltrative, micronodular), recurrent tumors, and poorly defined borders reduce this clearance rate significantly. In these cases, Mohs surgery provides superior outcomes because it examines 100% of the margin rather than relying on fixed-width excision.
3. Why do some skin cancers only get shaved while others need Mohs?
Superficial BCCs and low-risk SCCs that are small, well-defined, and in non-critical locations can sometimes be adequately treated with shave removal, curettage, or standard excision. The decision is based on tumor-specific risk factors: type, size, location, histologic subtype, and depth of invasion. Your dermatologist assesses all of these to determine the approach that gives you the best outcome.
4. Does Mohs surgery leave a bigger scar than regular excision?
Usually the opposite. Because Mohs examines the entire margin and removes tissue only where cancer persists, the final wound is typically smaller than what standard excision with predetermined margins would produce. Additionally, the Mohs surgeon performs immediate reconstruction with full knowledge of the defect, which usually produces a better cosmetic result than delayed repair.
5. My primary care doctor said I just need it "cut out." Should I still see a Mohs surgeon?
That depends on the tumor. For low-risk BCCs in non-critical locations, standard excision by an experienced surgeon may be perfectly appropriate. However, for tumors on the face (especially nose, eyelids, ears, and lips), recurrent tumors, aggressive subtypes, or large tumors, the evidence strongly supports Mohs surgery. A consultation with a fellowship-trained Mohs surgeon ensures you get the right treatment for your specific situation.
6. How long does Mohs surgery take?
Most Mohs procedures are completed in two to four hours, including the reconstruction. The surgery itself involves alternating between tissue removal and microscopic examination, with each stage taking approximately 30–45 minutes for lab processing. Patients wait comfortably between stages. One to three stages are typical.
7. Is Mohs surgery covered by insurance?
Yes. Mohs surgery is covered by Medicare and virtually all private insurance plans when performed for appropriate indications. The AAD/ACMS appropriate use criteria provide the evidence-based framework that insurers reference when evaluating coverage (Connolly et al., 2012).
8. Are melanoma margins different from other skin cancer margins?
Yes. Melanoma margins are determined by Breslow thickness (how deep the melanoma grows) rather than by the visible size of the tumor. Current guidelines recommend 0.5–1 cm for melanoma in situ, 1 cm for thin melanoma (up to 1 mm), 1–2 cm for intermediate melanoma (1.01–2 mm), and 2 cm for thick melanoma (over 2 mm). These margins were established by six randomized controlled trials conducted over four decades (Sharib et al., 2022).
9. What does "subclinical extension" actually mean?
Subclinical extension refers to cancer cells that extend beyond the visible border of a tumor into tissue that appears normal to the naked eye. Every skin cancer has some degree of subclinical extension — this is the biological reason surgical margins exist. The unpredictable nature of subclinical extension is also why Mohs surgery, which maps the exact boundary of the cancer under a microscope, produces better outcomes than fixed-margin excision for high-risk tumors.
10. What is the difference between bread-loaf pathology and Mohs margin examination?
In standard excision, the removed tissue is cut into thin vertical slices (like slicing a loaf of bread) and a pathologist examines representative sections. This "bread-loaf" method examines roughly 1% of the true surgical margin — some studies estimate as low as 0.2%. Mohs surgery, by contrast, processes tissue so that 100% of the peripheral and deep margins are examined. Cancer present in the 99% of margin that bread-loaf sectioning misses is the primary reason standard excision has higher recurrence rates (Helm et al., 2024).
References
Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123(3):340-344. PMID: 3813602
Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15(3):315-328. PMID: 2646336
Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15(4):424-431. PMID: 2925988
Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241-248. PMID: 1430364
Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1992;26(6):976-990. PMID: 1607418
Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet. 2004;364(9447):1766-1772. PMID: 15541449
Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery. J Am Acad Dermatol. 2012;67(4):531-550. PMID: 22959232
van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011-3020. PMID: 25262378
Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540-559. PMID: 29331385
Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578. PMID: 29331386
Murray C, Sivajohanathan D, Hanna TP, et al. Patient indications for Mohs micrographic surgery: a systematic review. J Cutan Med Surg. 2019;23(1):75-90. PMID: 30033747
Quazi SJ, Aslam N, Saleem H, et al. Surgical margin of excision in basal cell carcinoma: a systematic review of literature. Cureus. 2020;12(7):e9211. PMID: 32821563
Cerci FB, Kubo EM, Werner B, et al. Surgical margins required for basal cell carcinomas treated with Mohs micrographic surgery according to tumor features. J Am Acad Dermatol. 2020;83(2):493-500. PMID: 32289390
Ünverdi ÖF, Yücel S, Aydoğan K. Recommended surgical margins for basal cell carcinoma: is 3 mm safe enough? Adv Skin Wound Care. 2020;33(4):209-212. PMID: 32195723
Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021;19(4):364-376. PMID: 33845460
Sharib J, Keung EZ, Gershenwald JE. Melanoma trials that defined surgical management: overview of trials that established NCCN margin guidelines. J Surg Oncol. 2022;125(1):28-33. PMID: 34897715
Stratigos AJ, Garbe C, Dessinioti C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment — Update 2023. Eur J Cancer. 2023;193:113252. PMID: 37708630
Zakhem GA, Pulavarty AN, Guo EL, et al. Association of patient risk factors, tumor characteristics, and treatment modality with poor outcomes in primary cutaneous squamous cell carcinoma. JAMA Dermatol. 2023;159(2):160-171. PMID: 36576732
Daviti M, Stieger C, Bänziger R, et al. Real-life data on the management of incompletely excised basal cell carcinoma. Dermatology. 2023;239(3):429-435. PMID: 36731436
Lacerda PN, Bittencourt FV, Gontijo GT, et al. Efficacy of micrographic surgery versus conventional excision in reducing recurrence for basal cell carcinoma and squamous cell carcinoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2024;38(6):1058-1069. PMID: 38116955
Helm TN, Marks JG Jr. Bread loaf sectioning provides variable (but sometimes considerable) useful information on margins. J Am Acad Dermatol. 2024;91(2):e37. PMID: 38614249
Moncrieff MD, Gyorki D, Gershenwald JE, et al. 1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study. Ann Surg Oncol. 2018;25(9):2541-2549. PMID: 29850955
About This Site
Skin Trust is a free educational website created by Dr. Thomas L.H. Hocker, M.D., M.Phil. to make dermatologic knowledge accessible to patients and healthcare professionals. All content is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Skin Trust is Dr. Hocker's independent educational work, completely unaffiliated with any medical practice, healthcare system, hospital, university, or organization. Using this website does not create a doctor-patient relationship. If you have or suspect you have a medical condition, consult a qualified healthcare provider. Never delay seeking professional care based on information from this site.
